These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 33939335)
1. Resected pancreatic adenocarcinoma: An Asian institution's experience. Ng KYY; Chow EWX; Jiang B; Lim C; Goh BKP; Lee SY; Teo JY; Tan DMY; Cheow PC; Ooi LLPJ; Chow PKH; Lee JJX; Kam JH; Koh YX; Jeyaraj PR; Tan EK; Choo SP; Chan CY; Chung AYF; Tai D Cancer Rep (Hoboken); 2021 Oct; 4(5):e1393. PubMed ID: 33939335 [TBL] [Abstract][Full Text] [Related]
2. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study. Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211 [TBL] [Abstract][Full Text] [Related]
3. The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy. Yamada D; Eguchi H; Iwagami Y; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Mori M; Doki Y Surg Today; 2018 Oct; 48(10):952-962. PubMed ID: 29770847 [TBL] [Abstract][Full Text] [Related]
4. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371 [TBL] [Abstract][Full Text] [Related]
5. Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-institutional Retrospective Study. Murakawa M; Yamamoto N; Kamioka Y; Kamiya M; Kobayashi S; Ueno M; Morimoto M; Atsumi Y; Aoyama T; Tamagawa H; Yukawa N; Rino Y; Masuda M; Morinaga S In Vivo; 2020; 34(1):347-353. PubMed ID: 31882498 [TBL] [Abstract][Full Text] [Related]
6. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy. Newhook TE; Prakash LR; Soliz J; Hancher-Hodges S; Speer BB; Wilks JA; Bruno ML; Dewhurst WL; Arvide EM; Maxwell JE; Ikoma N; Kim MP; Lee JE; Katz MHG; Tzeng CD J Surg Oncol; 2021 Dec; 124(8):1381-1389. PubMed ID: 34398988 [TBL] [Abstract][Full Text] [Related]
7. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective. Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192 [TBL] [Abstract][Full Text] [Related]
8. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update. Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639 [TBL] [Abstract][Full Text] [Related]
9. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy. Osipov A; Nissen N; Rutgers J; Dhall D; Naziri J; Chopra S; Li Q; Hendifar AE; Tuli R Ann Surg Oncol; 2017 Nov; 24(12):3674-3682. PubMed ID: 28871564 [TBL] [Abstract][Full Text] [Related]
10. The addition of radiation to chemotherapy does not improve outcome when compared to chemotherapy in the treatment of resected pancreas cancer: the results of a single-institution experience. Martin LK; Luu DC; Li X; Muscarella P; Ellison EC; Bloomston M; Bekaii-Saab T Ann Surg Oncol; 2014 Mar; 21(3):862-867. PubMed ID: 24046122 [TBL] [Abstract][Full Text] [Related]
11. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy. Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577 [TBL] [Abstract][Full Text] [Related]
12. [Surgical therapy of pancreatic cancer - 5 years survival]. Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data. Chikhladze S; Lederer AK; Kousoulas L; Reinmuth M; Sick O; Fichtner-Feigl S; Wittel UA World J Surg Oncol; 2019 Nov; 17(1):185. PubMed ID: 31706323 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267 [TBL] [Abstract][Full Text] [Related]
15. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign? Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782 [TBL] [Abstract][Full Text] [Related]
16. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature. Lovecek M; Skalicky P; Chudacek J; Szkorupa M; Svebisova H; Lemstrova R; Ehrmann J; Melichar B; Yogeswara T; Klos D; Vrba R; Havlik R; Mohelnikova-Duchonova B World J Gastroenterol; 2017 Sep; 23(35):6420-6428. PubMed ID: 29085191 [TBL] [Abstract][Full Text] [Related]
17. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas. Downs-Canner S; Zenati M; Boone BA; Varley PR; Steve J; Hogg ME; Zureikat A; Zeh HJ; Lee KK J Surg Oncol; 2015 Jul; 112(1):80-5. PubMed ID: 26153355 [TBL] [Abstract][Full Text] [Related]
18. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Li B; Shen S; You S; Zhang G; Gao S; Shi X; Wang H; Yin X; Xu X; Guo S; Jin G BMC Cancer; 2021 May; 21(1):612. PubMed ID: 34034684 [TBL] [Abstract][Full Text] [Related]
19. The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma. Thomas RM; Truty MJ; Kim M; Kang Y; Zhang R; Chatterjee D; Katz MH; Fleming JB Ann Surg Oncol; 2015; 22(6):1884-92. PubMed ID: 25404477 [TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]